Holen Sie sich die Stockscreener-App
3.35
2.33%
-0.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.43
Offen:
$3.42
24-Stunden-Volumen:
6.27M
Relative Volume:
0.43
Marktkapitalisierung:
$1.38B
Einnahmen:
$263.44M
Nettoeinkommen (Verlust:
$-390.98M
KGV:
-2.9884
EPS:
-1.121
Netto-Cashflow:
$-336.24M
1W Leistung:
+0.90%
1M Leistung:
-34.70%
6M Leistung:
+51.58%
1J Leistung:
+11.67%
1-Tages-Spanne:
$3.33
$3.485
1-Wochen-Bereich:
$3.32
$3.65
52-Wochen-Spanne:
$1.6385
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
3.35 | 1.41B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
436.18 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.56 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.89 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.16 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.78 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN
IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm
Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote, News & History - Benzinga
Why is Iovance Biotherapeutics Inc stock going up2026 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices - Sahm
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - msn.com
Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More - GlobeNewswire Inc.
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Market Outlook: Is Iovance Biotherapeutics Inc a stock for growth or value investors2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Volume Recap: Is Iovance Biotherapeutics Inc still a buy after recent gains2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
IOVA | Iovance Biotherapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics (MIL:1IOVA) NonCurrent Deferred Rev - GuruFocus
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Iovance downgraded to Neutral at UBS related to Amtagvi concerns - MSN
Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript - GuruFocus
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial - MarketBeat
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Advanced Cell-based Therapy Booming the Success for Healthcare Sector - Sahm
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - sahmcapital.com
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - simplywall.st
Iovance Biotherapeutics Announces Upcoming Board Member Retirement - The Globe and Mail
Iovance Biotherapeutics board member Wendy Yarno to retire after current term - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 20 March - Investing.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting - Stock Titan
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeu - The National Law Review
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (IOVA) Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational TrialWhat's Changed - Sahm
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics (IOVA) announces positive early data for lifileucel TIL therapy in advanced sarcomas - MSN
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
39,059 |
0 |
257,590 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
142,394 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 02 '26 |
Option Exercise |
0.00 |
52,087 |
0 |
516,609 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,307 |
0 |
118,051 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
221,329 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,697 |
0 |
124,353 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 24 '26 |
Option Exercise |
0.00 |
120,000 |
0 |
173,546 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
39,996 |
0 |
69,996 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,906 |
0 |
113,640 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):